All papersGenerative AI & DiffusionDuke University

A Novel Conditional Adversarial Diffusion Model for High-Fidelity OCT-to-OCT Image Translation and Precise Anti-VEGF Therapy Response Prediction in Diabetic Macular Edema

/ Paper arXiv 2611.03958

Key numbers

5-foldThe model was developed with subject-level 5-fold cross-validation on a US cohort
85.7%with balanced accuracies of 85.7% and 93.0% on the US cohort and 85.2% and 95.3% on…
85.2%…85.7% and 93.0% on the US cohort and 85.2% and 95.3% on the external Iranian cohort…

From the paperCopied from the abstract, not written by AI.

Abstract

From the paperThe authors' own words.

Diabetic macular edema (DME) is a leading cause of severe vision loss among working-age adults. Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections currently serve as the first-line therapy for DME, a notable subset of patients fails to respond despite the substantial cost and clinical burden, suggesting they may benefit more from alternative interventions. Automated, noninvasive pre-treatment response assessment could therefore spare non-responders from the current trial-and-error treatment paradigm. In this study, we propose a novel conditional adversarial diffusion framework that synthesizes post-treatment optical coherence tomography (OCT) images from baseline scans, enabling the derivation of each patient's initial response to anti-VEGF therapy. The model was developed with subject-level 5-fold cross-validation on a US cohort (n = 127) and externally validated on an independent Iranian cohort (n = 44). Benchmarked against fourteen baseline and state-of-the-art translation models, the proposed model achieved the best treatment-response prediction performance among the methods evaluated for that task on both cohorts, with balanced accuracies of 85.7% and 93.0% on the US cohort and 85.2% and 95.3% on the external Iranian cohort at the 10% and 20% central subfield thickness reduction thresholds, respectively. Ultimately, this framework offers a decision-support tool to help ophthalmologists anticipate initial anti-VEGF outcomes in DME prior to treatment initiation, toward personalized therapy selection. The source code will be made publicly available upon acceptance.

From the full paper

From the paperCopied from the paper itself by our code.

Reading the paper on arXiv…

Ask this paper

/ Ask a questionAnswers come from the full paper and name the section

    / Your notes

    Select text in the abstract to highlight it or add a note. They stay in this browser.

      Read the PDF